SCHEMBL6327577

SCHEMBL6327577

CCCCC(C(=O)N(C)C1CCCCC1)N1CCC(CNC(=O)c2cc(Cl)c(N)nc2OC)CC1

nearest known ligand 0.45

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.41
HTR4 Q13639 9/20 0.39
ACHE P22303 1/20 0.38
DRD4 P21917 2/20 0.37
DRD3 P35462 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6327384 0.91 HTR4 (0.42) DRD2HTR4DRD4DRD3
SCHEMBL6329824 0.88 HTR4 (0.44) DRD2HTR4DRD4DRD3
SCHEMBL6329808 0.86 HTR4 (0.41) DRD2HTR4DRD4DRD3
SCHEMBL6328782 0.85 HTR4 (0.43) DRD2HTR4DRD4DRD3
SCHEMBL6326744 0.83 NR4A2 (0.37) HTR4ACHE
SCHEMBL7259550 0.79 HTR4 (0.49) HTR4
SCHEMBL6333842 0.78 HTR4 (0.58) HTR4ACHE
SCHEMBL6329052 0.77 HTR4 (0.60) HTR4ACHE
SCHEMBL6327502 0.73 HTR4 (0.58) HTR4
SCHEMBL7259533 0.72 HTR4 (0.53) HTR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6979690-B2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC. (US) 2005-12-27 US disclosed
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators PFIZER INC 2003-11-06 US disclosed
EP-1325921-A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Pfizer Inc. (US) 2003-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207875-A1 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators HRH4, HRH2, HTR4 DRD2 262/4885HTR4 3/4885ACHE 3937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.